Details

Autor(en) / Beteiligte

• Tavakoli, Sahar
• Khalaj, Fattaneh
• Kasaeian, Amir
• Mousavi, Seyed Ali
• Mousavian, Amir-Hossein
• Arabi, Fatemeh
• Rad, Soroush
• Rostami, Shahrbano
• Barkhordar, Maryam
• Biglari, Mohammad
• Mardani-Fard, Heydar Ali
• Alemi, Hediyeh
• Khavandgar, Naghmeh
• Kamranzadeh Fumani, Hossein
• Janbabai, Ghasem
• Mousavi, Seied Asadollah
• Ghavamzadeh, Ardeshir
• Vaezi, Mohammad

Titel

Comparable Outcomes of Pre- Versus Post-Tyrosine Kinase Inhibitor Era Treatment in Chronic Myeloid Leukemia: A Retrospective Cohort Study With Long-term Follow-up

Ist Teil von

• Cell transplantation, 2023-01, Vol.32, p.9636897231163212-9636897231163212

Ort / Verlag

United States: SAGE Publications

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was introduced after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with chronic myeloid leukemia (CML). However, the long-term effects of allo-HSCT in chronic phase CML patients are mostly unknown. We retrospectively analyzed the outcomes of 204 patients with sibling donors who received peripheral stem cells and underwent allo-HSCT of chronic phase I (CP1) in the pre- and post-TKI era at Shariati Hospital in Tehran, Iran, from 1998 to 2017 and followed up till the end of 2021. The median follow-up time for all patients was 8.7 (SD = 0.54) years. Fifteen-year overall survival (OS), disease-free survival (DFS), graft-versus-host disease-free relapse-free survival (GRFS), relapse, and non-relapse mortality (NRM) incidence were 65.70%, 57.83%, 17.56%, 13.17%, and 28.98%, respectively. Using multivariable analyses, the only risk factor increasing the hazard of death was the time between diagnosis to allo-HSCT greater than 1 year compared to this time less than 1 year by 74% [hazard ratio (HR) = 1.74, = 0.039]. Also, age is a significant risk factor for DFS (HR = 1.03, = 0.031). Our findings suggested that allo-HSCT is still an important treatment option for CP1 patients, especially those resistant to TKI treatment. TKI consumption can have a desirable effect on NRM after allo-HSCT for CP1 CML.